Lisata Therapeutics to Connect with Investors in November
Lisata Therapeutics, Inc. (NASDAQ: LSTA), a prominent clinical-stage pharmaceutical company focused on innovative therapies for advanced solid tumors and serious diseases, is excited to share its participation in several key industry events this November. These engagements provide opportunities for the company to connect with investors and industry leaders.
Key Upcoming Events
BIO-Europe
The BIO-Europe event will take place from November 4-6, 2024, with additional virtual participation available on November 12-13, 2024. This format allows attendees from around the globe to engage in meaningful discussions and network effectively. Tariq Imam, the company’s Vice President of Business Development and Operations, will represent Lisata at this significant gathering.
PEGS Europe Summit
Following BIO-Europe, the PEGS Europe Summit will be held from November 5-7, 2024, in Barcelona, Spain. On November 5th at 3:20 p.m. CEST, David J. Mazzo, PhD, President and CEO of Lisata Therapeutics, will present the company’s latest advancements. This summit is an excellent platform for scientists and decision-makers to explore innovative biologics manufacturing, including therapeutic proteins and antibodies.
LSX Inv€$tival Showcase
The LSX Inv€$tival showcase is another exciting event, scheduled for November 18, 2024, at Tobacco Dock in the UK. Once again, Dr. Mazzo will present, this time at 1:00 p.m. GMT. This showcase emphasizes connecting investors with medical innovations that are shaping the future of healthcare.
Exploring Lisata Therapeutics' Innovations
Lisata Therapeutics is dedicated to the discovery, development, and commercialization of therapies for difficult-to-treat conditions, notably advanced solid tumors. A key focus of their pipeline is the cyclic peptide product candidate known as certepetide. This investigational drug aims to revolutionize cancer treatment by allowing for more effective targeting of tumors.
The innovative technology, known as the CendR Platform, is designed to enhance the effectiveness of therapeutic agents by enabling them to specifically target and penetrate solid tumors. Through strategic partnerships and robust research and development efforts, Lisata is paving the way for new treatments that can significantly impact patient outcomes.
Future Milestones
Lisata Therapeutics anticipates announcing several important milestones in the coming months. The company is optimistic that its current funding will support operations into 2026, which will include data milestones from ongoing clinical trials aimed at bringing new solutions to market.
As the company prepares for these events, it’s clear that Lisata Therapeutics is on a strong trajectory, committed to advancing its pipeline and fostering relationships with investors, stakeholders, and the broader healthcare community.
Frequently Asked Questions
What will Lisata Therapeutics present at the BIO-Europe event?
Tariq Imam will engage in one-on-one meetings to discuss Lisata's innovative therapies targeting advanced solid tumors.
Who will represent Lisata at the PEGS Europe Summit?
David J. Mazzo, PhD, the President and CEO, will present detailed insights into the company’s advancements.
What is the goal of the LSX Inv€$tival showcase?
The showcase aims to connect investors with groundbreaking medical innovations and facilitate meaningful discussions surrounding future investments.
What is the significance of certepetide in Lisata's pipeline?
Certepetide is designed to enhance the effectiveness of anti-cancer drugs by allowing them to target and penetrate solid tumors more effectively.
What are Lisata’s plans for the future?
Lisata Therapeutics expects to announce multiple milestones over the next year and a half, aiming to support ongoing clinical trials and innovative research.
